A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults

Inclusion Criteria: * Male or female assigned at birth, inclusive of all gender identities * Between, and including, 18 and 40 years of age on the day of the Screening Visit * Healthy individual, as established by the Investigator * Able to read and understand the informed consent form, and written informed consent obtained from the participant * Participants who, in the opinion of the Investigator, can and will comply with the requirements of the protocol Exclusion Criteria: * Body Mass Index \< 18.0 or \> 32.0 kg/m2 * Use of any investigational or non-registered product other than the study vaccination within 1 month preceding study entry, or concurrent participation in another clinical study in which the participant has been or will be exposed to an investigational or non-registered product, at any time during the study period * Administration / planned administration of any vaccine not foreseen by the study protocol within 1 month preceding the first study vaccination and up to 1 month after the last study vaccination * Presence of serologic marker of acute, chronic or past HBV infection * Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months preceding first study vaccination, or planned chronic administration at any time during the study period * Administration of long-acting immune-modifying drugs within 6 months or 5 half-lives (whichever is longer) preceding first study vaccination, or planned administration at any time during…